Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Germany research report

Read a source-linked Germany psilocybin research report with live indexed trial statistics, EPIsoDE evidence, research sites and dated access context.

Free access · No subscription for research tools or data exports

Germany: research and access context

Editorial sources checked . Registry facts refresh separately; the latest indexed registry check is Nov 19, 2026 02:23 UTC. This report covers psilocybin and psilocin, not the entire psychedelic sector.

Controlled substances

Psilocybin and psilocin are listed in Anlage I of the BtMG. This controlled status and any authorised research or exceptional-access pathway must be considered separately.

Confirmed cohort programme

The BfArM table lists psilocybin for treatment-resistant depression under the Central Institute of Mental Health, with confirmed notification dated 18 June 2026 and programme duration through 17 June 2027. A listed programme is not general marketing authorisation or a promise of eligibility.

Published German evidence

EPIsoDE is a published randomized report, not evidence inferred from registration. Its primary response comparison was not significant. Read the endpoint, safety findings and limitations before interpreting exploratory symptom changes.

Mannheim and Berlin

ZI Mannheim describes research with Charité and MIND Foundation, and the exceptional-access programme at ZI and OVID Berlin. These organisations have different research, education and treatment roles; inclusion is not an endorsement.

Access, payment and evidence are separate questions

The BfArM procedure and AMHV concern cohort programmes, not individual named-patient applications. Current entry criteria and capacity must be checked with the responsible programme. A registry recruitment flag does not establish personal eligibility.

The G-BA explanation of AMNOG describes added-benefit assessment and its role in reimbursement pricing. It does not establish a psilocybin reimbursement decision. This report does not assert routine insurance coverage, a treatment price, or a regulatory approval forecast.

Explore registry geography and organisations

Reset

1 trials match this view; 2 reported facilities; 2 have usable coordinates. Latest indexed registry check Nov 19, 2026 02:23 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 144 across 1 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

20211

Current indexed registry status

Completed1

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Matching trial records

1 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression

NCT04670081

Treatment-resistant Depression
Central Institute of Mental Health, Mannheim

PHASE2

Completed

Registry updated 2025-01-20

144

ACTUAL

2021-06-10
2024-02-27
2024-12-11
Evidence-guide report · Mertens et al. · EPISODE · 2026

Reported research facilities

Central Institute of Mental Health (CIMH)Mannheim, Germany · Coordinates available · Selected-country site
Charité Berlin, Campus Mitte, Department of Psychiatry and PsychotherapyBerlin, Germany · Coordinates available · Selected-country site

This directory includes reported facilities with and without coordinates. For a country-filtered view, locations are labeled as selected-country sites or international sites of matching trials. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.